The Janssen Pharmaceutical Companies of Johnson & Johnson signed a Memorandum of Understanding on strategic collaboration with Amoy Diagnostics Co Ltd (AmoyDx) on Sunday to reinforce its partnership with local diagnostic companies in building a collaborative biopharmaceutical ecosystem that will optimize drug life cycle and empower full-cycle patient management.

According to the MoU, both companies will forge a synergized end-to-end working model spanning market access, medical professional and patient education, big data platform construction, as well as research and development in areas such as biomarkers.

The partnership with the local diagnostic company will further empower full-cycle patient management in various ways, including fast reimbursement to optimize the diagnosis of Janssen's target therapeutic areas such as lung cancer and urothelial cancer.

The partnership will also support patients' early access to transformational treatment solutions under the country's pilot policies, such as the Plan for the Development of Innovative Regulatory of Drugs and Medical Devices in the Guangdong-Hong Kong-Macao Greater Bay Area that allows medicines approved outside the Chinese mainland to be utilized by doctors.

The cooperation will also drive personalized medicine, the integration of diagnosis and treatment, optimize clinical development programs and explore emerging R&D opportunities to sustain the discovery, development, and delivery of transformational medicines for patients in need.

"As a transformational medical innovator and one of the first multinational pharmaceutical companies in China, Janssen remains imaginative and aggressive in partnering and creating win-win situations to deliver remarkable solutions. We aim to continue creating value for patients, healthcare professionals, and healthcare systems in China and across the globe," said Jenny Zheng, president of Janssen China.

"Through this strategic partnership with Janssen China, AmoyDx is dedicated to providing innovative medical solutions, facilitating the development of China's precision medicine, and accelerating access to transformational treatment solutions to improve patient outcomes," said Zheng Limou, chairman of AmoyDx.